The company expects the European Commission (EC) to make a final decision on the marketing authorization in June 2025.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and ...

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news ...

Acurx Pharmaceuticals (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced ...

Washington’s NFL franchise is set to return to the nation’s capital as part of an agreement between the organization and the ...

Prepare for the week ahead! Find out why we're watching Chewy ( CHWY), Meta Platforms (META) — and 3 more high-conviction picks. We'll be in your inbox every morning Monday-Saturday with all the ...